Journal
TRENDS IN MOLECULAR MEDICINE
Volume 19, Issue 6, Pages 329-335Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2013.03.002
Keywords
CD95; FAS; apoptosis; tumorigenesis; clinical studies; cancer therapy
Funding
- German Research Foundation (DFG) [SFB873]
- Helmholtz Alliance on Systems Biology (SB Cancer)
- German Ministry of Education and Research (BMBF)
- German Cancer Research Center (DKFZ)
- DAAD-LaCaixa scholarship
- National Center for Tumor Diseases (NCT)
Ask authors/readers for more resources
The role of CD95 (Fas/Apo1) in cancer has been a matter of debate for over 30 years. First discovered as an apoptosis-inducing molecule, CD95 soon emerged as a potential anticancer therapy. Yet accumulating evidence indicates a profound role for CD95 in alternative nonapoptotic signaling pathways that increase tumorigenesis. This fact challenges the initial clinical idea of using CD95 as a 'tumor killer' while setting the stage for clinical studies targeting the nonapoptotic signaling branch of CD95. This review summarizes the findings surrounding manipulation of the CD95 pathway for cancer therapy, considering how one receptor can both promote and prevent cell growth.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
